Holger Raviol is a biologist by training and has been working for the Roche Pharma branch since 2006. He held different roles in the Technical (CMC) Regulatory organization over the last 13 years. Holger started his professional career at the Roche Mannheim manufacturing site, gaining experience in technical and regulatory aspects of manufacturing and testing sterile drug products. Besides the regulatory life-cycle activities for commercialized products, Holger participated in the authoring of global new market applications (e.g. Perjeta, Gazyva, Tecentriq) which were launched out of Mannheim. Since 2016, Holger is based in Basel and involved in a variety of projects within the regulatory as well as the broader technical operations organization. With the onset of the COVID-19 pandemic, he took over the lead of the technical regulatory activities to enable the repurposing of an approved commercial drug for treatment of COVID-10 patients.